Literature DB >> 15855651

Deletion of Bid impedes cell proliferation and hepatic carcinogenesis.

Li Bai1, Hong-Min Ni, Xiaoyun Chen, Daniell DiFrancesca, Xiao-Ming Yin.   

Abstract

Mechanisms that control the proliferation capability of the initiated cells during hepatocarcinogenesis are still largely unclear. We investigated the role of a pro-death Bcl-2 family protein, Bid, in liver tumor development using a neonatal diethylnitrosamine model. Diethylnitrosamine was administrated to 15-day-old wild-type and bid-null mice. The development of microfoci at the early stage and of gross tumors at the later stage was compared between the two groups of mice. Both microfoci and gross tumor development were significantly retarded in the bid-null mice, despite reduced cell death as measured by TUNEL staining. Further studies indicated that there were significantly less proliferating cells in diethylnitrosamine-treated bid-null livers. The regulation of cell proliferation by Bid was confirmed in two other systems not involving carcinogenesis. Hepatocyte proliferation following partial hepatectomy and T lymphocyte proliferation following anti-CD3 stimulation were both retarded in bid-null mice. Thus, these studies revealed a previously undisclosed function of Bid in regulating cell proliferation, which can be important to tumor development. Furthermore, the role of Bid in promoting hepatocarcinogenesis is in contrast to its reported role in suppressing myeloid leukemia and thus suggests an organ- and/or etiology-specific role of the Bcl-2 family proteins in regulating oncogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855651      PMCID: PMC1606404          DOI: 10.1016/S0002-9440(10)62368-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

Review 1.  Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle.

Authors:  S V Ekholm; S I Reed
Journal:  Curr Opin Cell Biol       Date:  2000-12       Impact factor: 8.382

Review 2.  The Bcl-2 family: roles in cell survival and oncogenesis.

Authors:  Suzanne Cory; David C S Huang; Jerry M Adams
Journal:  Oncogene       Date:  2003-11-24       Impact factor: 9.867

3.  Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice.

Authors:  K L Murphy; F S Kittrell; J P Gay; R Jäger; D Medina; J M Rosen
Journal:  Oncogene       Date:  1999-11-11       Impact factor: 9.867

4.  BAD/BCL-[X(L)] heterodimerization leads to bypass of G0/G1 arrest.

Authors:  A Chattopadhyay; C W Chiang; E Yang
Journal:  Oncogene       Date:  2001-07-27       Impact factor: 9.867

5.  Bax accelerates tumorigenesis in p53-deficient mice.

Authors:  C M Knudson; G M Johnson; Y Lin; S J Korsmeyer
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

6.  Bcl-2 delays and alters hepatic carcinogenesis induced by transforming growth factor alpha.

Authors:  M E Vail; R H Pierce; N Fausto
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

7.  Bcl-2 expression delays hepatocyte cell cycle progression during liver regeneration.

Authors:  Mary E Vail; Michelle L Chaisson; James Thompson; Nelson Fausto
Journal:  Oncogene       Date:  2002-02-28       Impact factor: 9.867

8.  Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.

Authors:  C M Eischen; M F Roussel; S J Korsmeyer; J L Cleveland
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

9.  Bim is a suppressor of Myc-induced mouse B cell leukemia.

Authors:  Alexander Egle; Alan W Harris; Philippe Bouillet; Suzanne Cory
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

10.  BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia.

Authors:  S C Kogan; D E Brown; D B Shultz; B T Truong; V Lallemand-Breitenbach; M C Guillemin; E Lagasse; I L Weissman; J M Bishop
Journal:  J Exp Med       Date:  2001-02-19       Impact factor: 14.307

View more
  20 in total

1.  Bid-ding for mercy: twisted killer in action.

Authors:  A Egle; D Asslaber; A Villunger; J Pinon-Hofbauer
Journal:  Cell Death Differ       Date:  2013-07       Impact factor: 15.828

2.  Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation.

Authors:  A Wree; C D Johnson; J Font-Burgada; A Eguchi; D Povero; M Karin; A E Feldstein
Journal:  Cell Death Differ       Date:  2015-04-24       Impact factor: 15.828

3.  PUMA-mediated apoptosis drives chemical hepatocarcinogenesis in mice.

Authors:  Wei Qiu; Xinwei Wang; Brian Leibowitz; Wancai Yang; Lin Zhang; Jian Yu
Journal:  Hepatology       Date:  2011-10       Impact factor: 17.425

4.  Bid is a positive regulator for donor-derived lymphoid cell regeneration in γ-irradiated recipients.

Authors:  Hongmei Shen; Hui Yu; Paulina H Liang; Richard Xufeng; Yifang Song; Xiaoxia Hu; Xiaoyun Chen; Xiao-Ming Yin; Tao Cheng
Journal:  Exp Hematol       Date:  2011-06-16       Impact factor: 3.084

Review 5.  The Paradox of p53: What, How, and Why?

Authors:  Yael Aylon; Moshe Oren
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

6.  Bid agonist regulates murine hepatocyte proliferation by controlling endoplasmic reticulum calcium homeostasis.

Authors:  Hong-Min Ni; Catherine J Baty; Na Li; Wen-Xing Ding; Wentao Gao; Min Li; Xiaoyun Chen; Jianjie Ma; George K Michalopoulos; Xiao-Ming Yin
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

7.  Deficiency of Bid protein reduces sepsis-induced apoptosis and inflammation, while improving septic survival.

Authors:  Chun-Shiang Chung; Fabienne Venet; Yaping Chen; Leslie N Jones; Douglas C Wilson; Carol A Ayala; Alfred Ayala
Journal:  Shock       Date:  2010-08       Impact factor: 3.454

Review 8.  Rejuvenating Bi(d)ology.

Authors:  S S Zinkel; X M Yin; A Gross
Journal:  Oncogene       Date:  2012-10-15       Impact factor: 9.867

9.  The strength of the Fas ligand signal determines whether hepatocytes act as type 1 or type 2 cells in murine livers.

Authors:  Sven Schüngel; Laura Elisa Buitrago-Molina; Padmavathi devi Nalapareddy; Margitta Lebofsky; Michael P Manns; Hartmut Jaeschke; Atan Gross; Arndt Vogel
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

Review 10.  A fate worse than death: apoptosis as an oncogenic process.

Authors:  Gabriel Ichim; Stephen W G Tait
Journal:  Nat Rev Cancer       Date:  2016-07-01       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.